
    
      The investigators retrospectively analysed files of patients with advanced sarcoma not
      amenable to curative treatment, who were receiving an apatinib-containing regimen between
      June 1, 2015 and December 1, 2016. Fifty-six patients were included: 22 osteosarcoma, 10
      Ewing's sarcoma, 3 chondrosarcoma and 21 soft tissue sarcoma.
    
  